

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

The form must be received by Oncopeptides AB (publ) no later than Thursday, 3 December 2020.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Oncopeptides AB (publ), Reg. No. 556596-6438 at the Extraordinary General Meeting on Friday, 4 December 2020. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):

I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below

- Print, sign and send the form in the original to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to lisa.andersson@oncopeptides.com
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- A power of attorney shall be enclosed with the form if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must re-register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be received by Oncopeptides no later than **Thursday, 3 December 2020**. An advance vote can be withdrawn up to and including **Thursday, 3 December 2020**, by contacting Oncopeptides by e-mail to lisa.andersson@oncopeptides.com or by post to Oncopeptides AB (publ), Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Oncopeptides' webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Extraordinary General Meeting in Oncopeptides AB (publ) on Friday, 4 December 2020

The voting options below comprise the proposals included in the notice convening the Extraordinary General Meeting and have been provided on the company's website.

2. Election of chairman of the Extraordinary General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Election of one or two persons to approve the minutes
4.1 Tomas Nygren (Stiftelsen Industrifonden) Yes <input type="checkbox"/> No <input type="checkbox"/>
4.2 Marianne Nilsson (Swedbank Robur) Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Preparation and approval of voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination as to whether the Extraordinary General Meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Resolution on the introduction of a long term incentive program for the Company's employees in the US
7a. Proposal for resolution on adoption of a long term incentive program for the Company's employees in the US Yes <input type="checkbox"/> No <input type="checkbox"/>
7b. Proposal regarding issue of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. Proposal regarding equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
7d. Proposal regarding use of warrants issued in the Company's other incentive programs Yes <input type="checkbox"/> No <input type="checkbox"/>

The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued General Meeting
(Completed only if the shareholder has such a wish)
Item/items (use numbering):